



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome

Citation for published version:

Gathercole, LL, Hazlehurst, JM, Armstrong, MJ, Crowley, R, Boocock, S, O'Reilly, MW, Round, M, Brown, R, Bolton, S, Cramb, R, Newsome, PN, Semple, RK, Paisey, R, Tomlinson, JW & Geberhiwot, T 2016, 'Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome', *Liver International*, vol. 36, no. 11, pp. 1704-1712. <https://doi.org/10.1111/liv.13163>

Digital Object Identifier (DOI):

[10.1111/liv.13163](https://doi.org/10.1111/liv.13163)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Liver International

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome.

Abbreviated title: Hepatic and adipose phenotype in Alström syndrome

Laura L Gathercole^{*1}, Jonathan M Hazlehurst^{*1}, Matthew J Armstrong^{*2}, Rachel Crowley³, Sarah Boocock⁴, Michael W O'Reilly⁵, Maria Round⁶, Rachel Brown⁷, Shaun Bolton⁴, Robert Cramb⁴, Phillip N Newsome², Robert K Semple⁸, Richard Paisey⁹, Jeremy W Tomlinson^{§1}, Tarekegn Geberhiwot ^{§4,5}

*Denotes equal contribution

§ Corresponding authors and equal contribution

Affiliations

1. Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.
2. Centre for Liver Research and NIHR Liver Biomedical Research Unit, University of Birmingham, Birmingham, UK.
3. St Vincent's Hospital, Elm Park, Merrion Rd, Dublin 4, Ireland and University College, Dublin, Ireland.
4. Department of Endocrinology and Metabolism, University Hospitals Birmingham, Birmingham, UK.
5. Centre for Diabetes, Endocrinology and Metabolism, University of Birmingham, Birmingham, UK.
6. Department of Gastroenterology, University Hospitals Birmingham, Birmingham, UK.
7. Department of Pathology, University Hospital of Birmingham, Birmingham, UK.

8. Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
9. Diabetes Research Unit, Horizon Centre, Torbay Hospital NHS Foundation Trust, Torquay, UK.

Corresponding Authors:

Dr Tarekegn Geberhiwot, Department of Endocrinology, University Hospital of Birmingham, Birmingham, UK. tarekegn.geberhiwot@uhb.nhs.uk Tel: 0121 371 3958 Fax: 01213716990

Professor Jeremy W Tomlinson, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK. jeremy.tomlinson@ocdem.ox.ac.uk Tel: 01865 857359 Fax: 01865 857213

Total word count: 4997

Numbers of figures and tables: Figures 2 Tables 3

References: 38

Abbreviations:

NAFLD : non-alcoholic fatty liver disease

AS: Alström syndrome

BMI: body mass index

NASH: non-alcoholic steatohepatitis

ELF: Enhanced Liver Fibrosis

LSE: liver stiffness evaluations

PLAT: plasminogen activator

PLG: plasminogen

EDN1: Endothelin-1 (EDN1)

CTGF: connective tissue growth factor

TGF- β 3: transforming growth factor- β 3 ()

BMP 7: Bone morphogenetic protein 7

CCL2 and CCL3: chemokine (C-C motif) ligand 2 and 3

Competing interests: The authors declare they have no competing interests.

Disclosure summary: The authors have nothing to declare. This paper presents independent research and the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding:

This work was principally funded by Science Lottery Grant to ASUK and the NHS-England highly specialised service. Additional support was obtained from the Wellcome Trust (Clinical research Training fellowship to JMH ref. 104458/Z/14/Z) and through the NIHR Oxford Biomedical Research Centre. MOR was supported by Wellcome Trust Research fellowship (ref 099909). R.S. was supported by the Wellcome Trust [grant number WT098498] and the United Kingdom National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. PNN was supported by the National Institute For Health Research (NIHR) Birmingham Liver Biomedical Research Unit (BRU).

Abstract

Background and Aims: Alström syndrome (AS) is a recessive monogenic syndrome characterised by obesity, extreme insulin resistance and multi-organ fibrosis. Despite phenotypically being high risk of non-alcoholic fatty liver disease (NAFLD), there is a lack of data on the extent of fibrosis in the liver and its close links to adipose in patients with AS. Our aim is to characterise the hepatic and adipose phenotype in patients with AS.

Methods: Observational cohort study with comprehensive assessment of metabolic liver phenotype including liver elastography (Fibroscan®), serum Enhanced Liver Fibrosis (ELF) Panel and liver histology. In addition, abdominal adipose histology and gene expression was assessed. We recruited 30 patients from the UK national AS clinic. A subset of 6 patients underwent adipose biopsies which was compared with control tissue from 9 healthy participants.

Results: Patients were overweight/obese (BMI 29.3 (25.95-34.05) kg/m²). 80% (24/30) were diabetic. 74% (20/27) had liver ultrasound scanning suggestive of NAFLD. As judged by the ELF panel, 96 % (24/25) were categorized as having fibrosis and 10/21 (48 %) had liver elastography consistent with advanced liver fibrosis/cirrhosis. In 7/8 selected cases, there was evidence of advanced NAFLD on liver histology. Adipose tissue histology showed marked fibrosis as well as disordered pro-inflammatory and fibrotic gene expression profiles.

Conclusions: NAFLD and adipose dysfunction are common in patients with AS. The severity of liver disease in our cohort supports the need for screening of liver fibrosis in AS.

Abstract word count: 237

Keywords: NAFLD, Alström syndrome, Adipocyte biology, Insulin resistance

Key points:

- Alström Syndrome is a rare autosomal recessive monogenic ciliopathy
- Liver fibrosis and adipose fibrosis are common in patients with Alström Syndrome
- The liver fibrosis seen is more advanced than would be anticipated given the young age of the patients
- The liver fibrosis in Alström Syndrome can be identified non-invasively

Introduction:

Alström syndrome (AS) is a rare (1 per million) autosomal recessive [OMIM 203800] monogenic metabolic syndrome characterised by childhood onset obesity, extreme insulin resistance, diabetes, dyslipidaemia, hypertension and multi-organ fibrosis. Other features include retinal rod-cone dystrophy, hearing loss, and dilated cardio-myopathy [1]. Alström is caused by mutations in ALMS1 gene which encodes an ubiquitously expressed centrosomal protein of the primary cilium [2,3]. Cilia are membrane-bound, microtubular projections emanating from the cell surface and found on almost all vertebrate cells. Cilia sense a variety

of extracellular signals including hormones transducing them into intracellular signals [4]. ALMS1 protein is expressed in key metabolic tissue (liver, skeletal muscle, adipose and pancreas). *In vitro*, ALMS1 deletion is associated with hepatic lipid accumulation [5,6] and impaired adipocyte lipid storage [7,8]. Patients with AS have disordered lipid metabolism with elevated serum free fatty acids not suppressed by insulin [9] and have insulin resistance disproportionate to their BMI [10]. Additionally, we have described premature cardiovascular disease in patients with AS [11].

NAFLD is a spectrum ranging from simple steatosis, through to non-alcoholic steatohepatitis (NASH), fibrosis and an increased risk of cirrhosis and hepatocellular carcinoma. NASH, including cirrhosis and hepatocellular carcinoma, are becoming increasingly prevalent mirroring the obesity epidemic [12]. The relationship between obesity and NASH is well recognised at a population level, but the mechanism linking obesity to the development of NASH remains mostly speculative, partly due to a lack of well-defined human disease models. Patients with lipodystrophy, where mutations in several genes result in marked loss of adipose tissue mass and perturbed adipocyte function, develop profound insulin resistance and accelerated liver disease [13]. These severe hepatic consequences of frank anatomical deficiency of adipose tissue have been conceptually linked to the consequences of obesity by the notion of "adipose expandability" [14]. It follows that the ability of adipose tissue to store excess energy is finite, and when this limit is reached, whether at low absolute levels in lipodystrophy or at high absolute levels as in common obesity, lipotoxicity of distant organs results. Plausibly the adipose tissue dysfunction seen in AS may contribute to the liver phenotype although as ALMS1 is expressed within the liver and adipose it may also be via a direct effect of ALMS1 mutation within the liver.

Case reports and series [1,15–17] as well as our experience within the national AS clinic, reveals unexpectedly high incidence of liver cirrhosis and associated morbidity at a young

age. We have hypothesised that accelerated NAFLD in AS may relate to extreme insulin resistance and be driven (at least in part) by the inability of adipose tissue to provide a healthy adipose buffer. We have therefore undertaken the most detailed metabolic phenotyping of patients with AS published to date, and performed in-depth analysis of metabolic liver disease, incorporating adipose tissue morphology and gene expression profiles.

Patients and Methods

Patients and volunteers

Patients with AS were recruited from the UK National centre for AS service, based at Queen Elizabeth Hospital, Birmingham, UK. The diagnosis of AS was confirmed on the basis of clinical features and genetic sequencing of ALMS1 gene (**Supplementary table S1**). Informed consent was obtained and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in ethical approval by the Cornwall and Plymouth NRES (UKCRN 9044, REC approval 10/H0203/33). Data collected included patient demographics anthropometric measurements including body mass index (BMI) and blood pressure. Clinical phenotypes were recorded as well as details of diabetes status and management. A subset of patients consented for adipose tissue biopsy to examine the morphology of the adipose tissue and the expression of profibrotic genes. Control adipose tissue biopsies were taken from healthy individuals with ethical approval from West Midlands-Edgbaston NRES (LREC: 12/WM/0206). The liver biopsies included in this study were obtained for clinical reasons.

Serum analysis

Liver biochemistry, electrolytes, urea, creatinine, cholesterol, triglycerides, glycated haemoglobin, and full blood counts were measured using standard laboratory methods (Roche Modular system, Roche Ltd, Lewis, UK). Blood tests were taken in the non-fasting state.

Liver fibrosis

Patients underwent an abdominal ultrasound to looking for hepatic steatosis and for structural abnormalities associated with more advanced liver disease (splenomegaly, irregular portal vein blood flow and an irregular or nodular liver). Serum samples from AS patients were analysed for the Enhanced Liver Fibrosis panel (ELF), a well validated non-invasive biomarker to identify fibrotic liver disease [18]. Transient elastography was performed using Fibroscan® (Echosens, France). Only valid liver stiffness evaluations (LSEs) were recorded as per manufacturers guidance (10 readings, IQR <30% of the median LSE, success rate >60%). The cut-off of >7.9kPa was chosen as predictive for fibrosis as this has been shown to correlate well with histological findings in NAFLD [19].

Histological analysis of liver and adipose tissues

Liver histology was available for retrospective, review of the diagnosis, fibrosis stage (Kleiner) and NAFLD Activity Score (NAS) in 5 Alström syndrome patients and an additional 3 more histology reports were available for analysis. Liver biopsies were clinically indicated.

Six (20%) patients with AS and 9 controls had an abdominal subcutaneous adipose tissue biopsy performed under local anesthetic (1-2mL of 1% lidocaine), to obtain approximately 250-500mg of adipose tissue. The patients with AS who had adipose tissue biopsies were representative of the cohort as a whole (**Supplementary table 2**). The samples were divided into two and either placed in RNALater® (Ambion Inc., Austin, TX, USA) (initially for 24h at room temperature and then at -20°C) for subsequent gene expression analysis or placed into formalin for histological analysis.

Adipose tissue histology and gene expression

Adipose biopsies that were formalin-fixed were embedded in paraffin and cut at a thickness of 4µm on a Leica RM2235 microtome (Leica, Milton Keynes, UK) and stained with H&E and Van Gieson's to assess fibrosis.

RNA was prepared using RNeasy Lipid Tissue (QIAGEN). cDNA was generated from the RNA (QIAGEN RT² First Strand Kit) and expression of profibrotic genes was assessed using real-time reverse transcription array (RT² Profiler™ Arrays: Human fibrosis).

Statistical analysis

Unless otherwise stated data expressed is median (interquartile range). Gene expression data were obtained as Ct values (Ct is the cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine Δ Ct values [Δ Ct = (Ct of the target gene) – (Ct of the housekeeping gene)]. Fold change was calculated as $2^{-\Delta\Delta$ Ct [$\Delta\Delta$ Ct = (Δ Ct of the control group) – (Δ Ct of the patient group)]. Gene expression was analysed using available online software (<http://www.sabiosciences.com/pcrarraydataanalysis.php>).

Results

Demographic, genetic and metabolic characteristics

Demographic, anthropometric and metabolic data are presented in **Table 1** (mutation analysis **Supplementary Table 1**). Patients were predominantly male 70% (21/30) with a median age of 24 (21.5-37) years and a BMI of 29.3 (25.95-34.05) kg/m². The diabetes prevalence within the cohort was 80% with the duration of diabetes 11 (7.5-14.75) years. The prevalence of dyslipidaemia was high (total cholesterol 4.95 (4.2-6.3) mmol/L; high density lipoprotein cholesterol 0.89 (0.75-1.06) mmol/L; mean triglycerides 3.25 (2.1-4.75) mmol/ L). C-peptide to glucose ratios were elevated consistent with the anticipated insulin resistance and preserved β -cell function (4.72 (2.67-8.75) (ng/ml)/(mg/dl)*100).

Hepatic phenotype

Hepatic phenotypic data for individual patients is provided in **Table 2** with histology presented in **Figure 1** and **Table 3**. Median AST and ALT 32 (26-44) and 50 (33-76) IU/ L, respectively. 27/30 patients underwent abdominal ultrasound scanning. 20 of 27 (74%) had either an echobright liver consistent with hepatic steatosis or features suggestive of more advanced disease; in the absence of excess alcohol intake. Of these, 6 patients had splenomegaly (>13.5 cm) and 6 had ultrasound features suggestive of advanced fibrosis (coarse echotexture, irregular contour). The Enhanced Liver Fibrosis panel was performed in 25 patients, of whom 96 % were categorized as having either moderate or severe fibrosis. 21 patients underwent hepatic elastography (Fibroscan®, Echosens, France) with a valid liver stiffness evaluations (LSE), 48% (10/21) had a LSE of ≥ 7.9 kPa suggestive of hepatic fibrosis [20].

Formal histological analysis was available in 5 patients (17% study subjects) including the Kleiner fibrosis score and NAFLD activity score (**Table 3**). Additionally 2 post mortems and 1 liver biopsy report were available for inclusion although the tissue was not available for central reporting with Kleiner fibrosis score. These 2 post mortems confirmed cirrhosis of the liver with varices in these patients and the biopsy showed extensive fibrosis. In addition, subject 10 who is 19 years old had a liver biopsy at the age of 8 with extensive steatohepatitis predating diabetes by 9 years, indicating early onset severe NAFLD.

Adipose tissue gene expression and histology

The sub-group of patients who underwent adipose tissue biopsy (n=6, male/female=4/2) were representative of the AS cohort (**Supplementary Table S2**). The control volunteers (n=9) were exclusively female but were BMI- and age-matched to the patients.

Histology

Adipose tissue architecture and morphology were disrupted in patients with AS. Throughout the biopsies, there was extensive fibrosis evident on H & E staining (**Figure 2b.**) and confirmed using a Van Gieson stain (**Figure 2c**).

Gene expression

The abnormal adipose histology was reflected in the pattern of gene expression. The expression of multiple groups of genes involved in fibrosis was altered (**Figure 2d**). Genes important for fibrin degradation were reduced including tissue plasminogen activator (PLAT) and plasminogen (PLG). The expression of pro-inflammatory cytokines varied including reduction in IL-4 and IL-13 that are involved in promoting a pro-inflammatory macrophage population, as well as reductions in Endothelin-1 (EDN1) and connective tissue growth factor (CTGF) (fibroblast/myofibroblast activators). Furthermore, mRNA expression of

transforming growth factor- β 3 (TGF- β 3) was also decreased. In contrast, the expression of the genes encoding the chemotactic proteins, CCL2 and CCL3 (chemokine (C-C motif) ligand 2 and 3) increased.

Discussion

We have carried out the largest and most detailed metabolic and hepatic phenotypic description of patients with AS to date. Our study highlights that patients with AS are at an increased risk of advanced NAFLD and cirrhosis, which seems disproportionate to age, BMI and duration of diabetes. Our results indicate that their extreme insulin resistance and its attendant complications such as advanced NAFLD and cardiovascular events occur at a very young age in the presence of disorganised and dysfunctional adipocytes.

Consistent with previous data we have observed high levels of obesity and insulin resistance in AS patients. There are similarities between the clinical and biochemical profiles of individuals with AS and those with common obesity [1]. In contrast to common obesity, patients with AS invariably have childhood onset obesity, severe insulin resistance and very early occurrence of coronary heart disease before the age of 40 [11].

NAFLD ranges from relatively benign steatosis to cirrhosis. Our data revealed that a large proportion of patients with AS have evidence of NAFLD and advanced fibrosis at an early age. This supports published case reports and series that reveal unexpectedly high incidence of liver cirrhosis and associated mortality in Alström patients [1,15,16,21,22]. Our data, supports the need for early screening of liver fibrosis in patients with AS. Due to the rarity of the condition it is very difficult to validate the use of non-invasive markers of fibrosis in this setting. However, given the consistent accuracy and reproducibility of liver elastography (Fibroscan) in other liver diseases, we would advocate its use in AS to identify those in need of closer monitoring (i.e. for portal hypertension, liver cancer) and intensive metabolic optimisation.

Accelerated liver disease has also been reported in patients with lipodystrophies [13], and indeed this has been reported to be a major contributor to premature mortality in these

disorders. Like AS lipodystrophies are characterized by severe dyslipidaemic insulin resistance with attendant complications, and are exquisitely sensitive to variations in caloric and fat intake [23]. In contrast to AS, lipodystrophies are defined by partial or complete absence of adipose tissue, and often, though not always, feature low levels of adipocyte-derived hormones such as leptin. Lipodystrophies have thus been cited as monogenic evidence of the "adipose expandability" hypothesis [13,14,24]. Importantly, in some lipodystrophies, severe NAFLD arises even though the functional defect is restricted to adipose tissue, proving that NAFLD is not necessarily a liver autonomous process.

Unlike lipodystrophies, AS has been reported to feature excess obesity with abundant adipose tissue. It is plausible, however, that an adipose autonomous pro-fibrotic tendency in AS leads to a state of "relative" adipose failure more akin to the metabolic disease seen at high levels of "common" obesity. In keeping with this, patients with AS, like "common" obesity patients, can successfully ameliorate metabolic syndrome with lifestyle changes to offload adipose tissue [23]. The histological studies we report in a subset of AS patients may provide tissue-level support for this hypothesis: The increase in adipose tissue fibrosis may impair adipose lipid storage, increasing the likelihood of 'spill-over'. This is supported by increasing evidence of the adverse impact of adipose tissue fibrosis on metabolic flexibility [25], and recently published data suggest that adipose tissue fibrosis contributes to hepatic steatosis [26]. One example of this in a model organism is afforded by collagen VI-null ob/ob mice where reduced adipose tissue extracellular matrix permitted increased adipose depot size and adipocyte hypertrophy in response to high fat diet, and conferred metabolic protection even in the face of hyperphagia driven by leptin deficiency [25].

The pattern of gene expression that we observed in the adipose tissue was complex although several of the altered genes have been implicated in the pathogenesis of fibrosis, adipose dysfunction and global metabolic homeostasis. The TGF- β / BMP7 pathway is an important

regulator of fibrogenesis and we observed decreased expression of TGF- β 3 and BMP7 in adipose tissue from AS patients. BMP7 inhibits fibrogenesis [27] and, although TGF- β s are predominantly profibrotic, TGF- β 3 supports tissue repair and limits scar formation [28] . BMP7 also has metabolic effects on the adipose tissue driving adipogenesis in mesenchymal stem cells [29] and increasing mitochondrial activity and fatty acid oxidation in brown adipose tissue [30]. Additionally, it is an anorectic factor with a decrease in food intake [31] as well as increased energy expenditure [32] contributing to weight loss in mice with increased BMP7.

CCL2, whose expression was increased, has been implicated in steatohepatitis and metabolic dysfunction. CCL2 null mice have reduced hepatic fibrosis and markers of oxidative stress on a methionine/choline-deficient diet [33]. CCL2 overexpression leads to adipose inflammation and macrophage accumulation, systemic insulin resistance and hepatic steatosis [34].

The precise role of ALMS1 in adipocytes is not fully understood with expression falling early in differentiation yet unchanged by differentiation modulating agents [35]. Knockdown experiments have shown that reduced ALMS1 expression decreases adipogenesis with preserved insulin action [8]. ALMS1 knockout mice gain weight rapidly on an obesogenic diet (6 weeks) with adipose tissue mass expansion. However, over time, adipose tissue mass fails to expand further, contrasting with observations in wild type animals, and increasing body weight is driven by increased hepatic lipid loading [6]. ALMS1 has also been shown to regulate fibroblast function. In dermal fibroblasts derived from patients with AS, extracellular matrix production including collagen production was increased and the cells resisted apoptosis [36].

Given the available pre-clinical data the adipose phenotype that we have characterized may represent a combination of effects both on adipocyte development, but also modification of

the inflammatory and fibrotic response. The net effect is likely to be an impaired ability of adipocytes to effectively store lipid that may then be delivered to the liver to fuel the development of advanced NAFLD.

There are several limitations of the present study. Firstly, although our single-centre national service is the largest centre in the world, the ultra-rare nature of the syndrome led to the small numbers of study subjects precluded the ability to analyse clinical variables that may predict NAFLD progression to fibrosis within AS (i.e. multi-variate analysis). Although as in our cohort 28/29 (96.6%) patients had biallelic nonsense or frameshift mutations we have not found evidence that site of mutation dictates the extent of liver disease. Secondly, as this is a cross-sectional study not all patients' data is complete. However, as we were able to undertake several indices (biomarkers, transient elastography and histology) to assess the nature of NAFLD, we are able to offset missing variables. Thirdly, the control adipose biopsies were taken from female volunteers, however they were age and BMI matched. Finally, there is growing interest in genetic variants associated with NAFLD and in particular in patatin like phospholipase domain containing 3 (PNPLA3) which is associated not only with hepatic steatosis but in progression to fibrosis [37]. Additional genetic tests were beyond the scope of this study and would not alter the management of our patients who develop liver fibrosis at a much younger age than those seen in genome wide association studies. In general, its strengths lie: a) in the coherence of the patient group for an extremely rare monogenic metabolic disease; b) the in-depth characterisation of NAFLD and c) the link with adipose tissue structural and gene expression study.

In conclusion, our study highlight the importance of detailed assessment of the liver in patients with AS, as many harbour asymptomatic advanced fibrotic disease. This may have relevance to other related ciliopathies including Bardet Biedl syndrome where similar mechanisms may operate [38]. It is possible that adipose tissue dysfunction is an important

contributor to the severe NAFLD that we have described, but a causal link cannot be conclusively demonstrated from our cohort. Further studies are warranted to define the precise molecular pathways that are responsible for these observations in both liver and adipose tissue, and this may ultimately lead to the identification of regulatory pathways and novel therapeutic targets for the treatment of NAFLD.

Acknowledgements:

We would like to thank the patients and healthy volunteers for their willing participation in the study and Alström UK for support.

References:

1. Marshall JD, Bronson RT, Collin GB, Nordstrom AD, Maffei P, Paisey RB, et al. New Alström syndrome phenotypes based on the evaluation of 182 cases. *Arch. Intern. Med.* [Internet]. 2005 [cited 2015 Jul 10]; 165:675–83.
2. Hearn T, Spalluto C, Phillips VJ, Renforth GL, Copin N, Hanley NA, et al. Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. *Diabetes* [Internet]. 2005 [cited 2015 Apr 16]; 54:1581–7.
3. Collin GB, Marshall JD, Ikeda A, So WV, Russell-Eggitt I, Maffei P, et al. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alström syndrome. *Nat. Genet.* [Internet]. 2002 [cited 2015 May 6]; 31:74–8.
4. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. *N. Engl. J. Med.* [Internet]. 2011 [cited 2015 Jul 10]; 364:1533–43.
5. Collin GB, Cyr E, Bronson R, Marshall JD, Gifford EJ, Hicks W, et al. *Alms1*-disrupted mice recapitulate human Alström syndrome. *Hum. Mol. Genet.* [Internet]. 2005 [cited 2015 Apr 16]; 14:2323–33.
6. Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in *Alms1* mutant mice. *Biochem. Biophys. Res. Commun.* [Internet]. 2006 [cited 2015 Apr 27]; 342:1152–9.
7. Favaretto F, Milan G, Collin GB, Marshall JD, Stasi F, Maffei P, et al. GLUT4 defects in adipose tissue are early signs of metabolic alterations in *Alms1*^{GT/GT}, a mouse model for obesity and insulin resistance. *PLoS One* [Internet]. 2014 [cited 2015 Apr 16]; 9:e109540.
8. Huang-Doran I, Semple RK. Knockdown of the Alström syndrome-associated gene *Alms1* in 3T3-L1 preadipocytes impairs adipogenesis but has no effect on cell-autonomous insulin action. *Int. J. Obes. (Lond).* [Internet]. 2010 [cited 2015 Apr 28]; 34:1554–8.
9. Iannello S, Bosco P, Camuto M, Cavaleri A, Milazzo P, Belfiore F. A mild form of Alstrom disease associated with metabolic syndrome and very high fasting serum free fatty

- acids: two cases diagnosed in adult age. *Am. J. Med. Sci.* [Internet]. 2004 [cited 2015 Apr 16]; 327:284–8.
10. Minton JAL, Owen KR, Ricketts CJ, Crabtree N, Shaikh G, Ehtisham S, et al. Syndromic obesity and diabetes: changes in body composition with age and mutation analysis of ALMS1 in 12 United Kingdom kindreds with Alstrom syndrome. *J. Clin. Endocrinol. Metab.* [Internet]. 2006 [cited 2015 Apr 27]; 91:3110–6.
 11. Paisey RB, Smith J, Carey C, Barrett T, Campbell F, Maffei P, et al. Duration of Diabetes Predicts Aortic Pulse Wave Velocity and Vascular Events in Alström Syndrome. *J. Clin. Endocrinol. Metab.* [Internet]. 2015 [cited 2015 Jul 10]; :jc20151577.doi:10.1210/jc.2015-1577
 12. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. *Semin. Liver Dis.* [Internet]. 2008 [cited 2015 Jul 10]; 28:339–50.
 13. Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. *J. Hepatol.* [Internet]. 2013 [cited 2015 Jun 16]; 59:131–7.
 14. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. *J. Clin. Invest.* [Internet]. 2015 [cited 2015 Sep 15]; 125:1790–2.
 15. Awazu M, Tanaka T, Sato S, Anzo M, Higuchi M, Yamazaki K, et al. Hepatic dysfunction in two sibs with Alström syndrome: case report and review of the literature. *Am. J. Med. Genet.* [Internet]. 1997 [cited 2015 Jul 10]; 69:13–6.
 16. Bıyık M, Uçar R, Güngör G, Çakır ÖÖ, Esen H, Aksan S, et al. Alström syndrome with liver cirrhosis: first case from Turkey. *Turk. J. Gastroenterol.* [Internet]. 2013 [cited 2015 Jul 10]; 24:546–8.
 17. Connolly MB, Jan JE, Couch RM, Wong LT, Dimmick JE, Rigg JM. Hepatic dysfunction in Alström disease. *Am. J. Med. Genet.* [Internet]. 1991 [cited 2015 Apr 16]; 40:421–4.
 18. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* [Internet]. 2008 [cited 2015 May 6]; 47:455–60.
 19. Wong VW-S, Vergniol J, Wong GL-H, Foucher J, Chan HL-Y, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* [Internet]. 2010 [cited 2015 Jun 4]; 51:454–62.
 20. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. *J. Hepatol.* [Internet]. 2011 [cited 2015 Mar 17]; 54:650–9.
 21. Quiros-Tejeira RE, Vargas J, Ament ME. Early-onset liver disease complicated with acute liver failure in Alstrom syndrome. *Am. J. Med. Genet.* [Internet]. 2001 [cited 2015 Apr 16]; 101:9–11.
 22. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. *Diabetes* [Internet]. 1987 [cited 2015 Jan 8]; 36:914–24.
 23. Paisey RB, Geberhiwot T, Waterson M, Cramb R, Steeds R, Williams K, et al. Modification of severe insulin resistant diabetes in response to lifestyle changes in Alström syndrome. *Eur. J. Med. Genet.* [Internet]. 2014 [cited 2015 May 11]; 57:71–5.
 24. Huang-Doran I, Sleight A, Rochford JJ, O’Rahilly S, Savage DB. Lipodystrophy:

- metabolic insights from a rare disorder. *J. Endocrinol.* [Internet]. 2010 [cited 2015 May 4]; 207:245–55.
25. Khan T, Muise ES, Iyengar P, Wang Z V, Chandalia M, Abate N, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. *Mol. Cell. Biol.* [Internet]. 2009 [cited 2015 Apr 22]; 29:1575–91.
 26. du Plessis J, van Pelt J, Korf H, Mathieu C, van der Schueren B, Lannoo M, et al. Association of Adipose Tissue Inflammation With Histological Severity of Non-alcoholic Fatty Liver Disease. *Gastroenterology* [Internet]. 2015 [cited 2015 Jun 3]; doi:10.1053/j.gastro.2015.05.044
 27. Wang S-L, Yang C-Q, Qi X-L, Yuan M, Chang Y-Z, Yang L, et al. Inhibitory effect of bone morphogenetic protein-7 on hepatic fibrosis in rats. *Int. J. Clin. Exp. Pathol.* [Internet]. 2013 [cited 2015 May 14]; 6:897–903.
 28. Gómez-Gil V, Pascual G, Pérez-Köhler B, Cifuentes A, Buján J, Bellón JM. Involvement of transforming growth factor- β 3 and betaglycan in the cytoarchitecture of postoperative omental adhesions. *J. Surg. Res.* [Internet]. 2014 [cited 2015 May 14]; 187:699–711.
 29. Neumann K, Endres M, Ringe J, Flath B, Manz R, Häupl T, et al. BMP7 promotes adipogenic but not osteo-/chondrogenic differentiation of adult human bone marrow-derived stem cells in high-density micro-mass culture. *J. Cell. Biochem.* [Internet]. 2007 [cited 2015 May 14]; 102:626–37.
 30. Townsend KL, An D, Lynes MD, Huang TL, Zhang H, Goodyear LJ, et al. Increased mitochondrial activity in BMP7-treated brown adipocytes, due to increased CPT1- and CD36-mediated fatty acid uptake. *Antioxid. Redox Signal.* [Internet]. 2013 [cited 2015 May 14]; 19:243–57.
 31. Townsend KL, Suzuki R, Huang TL, Jing E, Schulz TJ, Lee K, et al. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. *FASEB J.* [Internet]. 2012 [cited 2015 May 14]; 26:2187–96.
 32. Tseng Y-H, Kokkotou E, Schulz TJ, Huang TL, Winnay JN, Taniguchi CM, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. *Nature* [Internet]. 2008 [cited 2015 Apr 20]; 454:1000–4.
 33. Galastri S, Zamara E, Milani S, Novo E, Provenzano A, Delogu W, et al. Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. *Clin. Sci. (Lond).* [Internet]. 2012 [cited 2015 May 14]; 123:459–71.
 34. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. *J. Clin. Invest.* [Internet]. 2006 [cited 2015 Mar 12]; 116:1494–505.
 35. Romano S, Milan G, Veronese C, Collin GB, Marshall JD, Centobene C, et al. Regulation of Alström syndrome gene expression during adipogenesis and its relationship with fat cell insulin sensitivity. *Int. J. Mol. Med.* [Internet]. 2008 [cited 2015 Apr 16]; 21:731–6.
 36. Zulato E, Favaretto F, Veronese C, Campanaro S, Marshall JD, Romano S, et al. ALMS1-deficient fibroblasts over-express extra-cellular matrix components, display cell cycle delay and are resistant to apoptosis. *PLoS One* [Internet]. 2011 [cited 2015 Apr 27]; 6:e19081.
 37. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*

[Internet]. 2010 [cited 2016 Feb 2]; 51:1209–17.

38. Pagon RA, Haas JE, Bunt AH, Rodaway KA. Hepatic involvement in the Bardet-Biedl syndrome. *Am. J. Med. Genet.* [Internet]. 1982 [cited 2015 May 12]; 13:373–81.

Figure legends

Figure 1. Liver histology from a patient with Alström syndrome Representative histology is shown for patient 15. A. 200 x magnification image of H&E stain showing macrovesicular steatosis and inflammation, inset panel is staining for cytokeratin. B. 200 x magnification image of Sirius Red stain.

Figure 2. Abdominal subcutaneous adipose tissue gene expression is deregulated in patients with Alström syndrome (n=6). Representative histological sections are presented in panels A-C (A. Control adipose H & E staining, B. Alström syndrome adipose H & E staining, C. Alström syndrome adipose Van Gieson staining D.) gene expression in panel E. (PLG=plasminogen, PLAT=tissue plasminogen activator, IL1 α = interleukin 1 α , IL4=interleukin 4, IL13=interleukin 13, IL13RA2=interlukin 13 receptor α 2, CCL2= chemokine ligand 2, CCL3= chemokine ligand 3, CCL11=chemokine ligand 11, IFN γ =intergeron γ , EDN1= endothelin 1, CTGF=connective tissue growth factor, MMP-1= matrix metallopeptidase 1, MMP-3= matrix metallopeptidase 3, BMP7= bone morphogenetic protein 7, TGF- β 3= transforming growth factor β 3, LTBP=latent transforming browth factor β binding protein 1, INHBE=inhibin β E, VEGFA=vascular endothelial growth factor A).

Table 1. The demographic and metabolic characteristics of 30 patients with Alström syndrome (BMI=body mass index; HbA1c=glycosylated haemoglobin; BP=blood pressure; HDL=high density lipoprotein cholesterol)

Table 2. The hepatic phenotype of 30 patients with Alström Syndrome. (M=male; F=female; N=no; Y=yes; Spleen=spleen enlarged; AST= aspartate aminotransferase; ALT=alanine aminotransferase; Plts=platelets; ELF=Enhanced liver fibrosis panel; None=not suggestive of fibrosis; Mod=predictive of moderate fibrosis; Severe=predictive of severe fibrosis; LSE=liver stiffness evaluation; NP=not predictive of fibrosis; Predictive=predictive of fibrosis; IQ=interquartile range; *Patients with liver histology available).

Table 3. Histological analysis of livers of patients with Alström syndrome. (M=male; F=female; IQR=interquartile range; NP=not predictive of fibrosis; NAS=non alcoholic fatty liver disease activity score.)

Table 1. The demographic and metabolic characteristics of 30 patients with Alström syndrome

n (Male/Female)	30 (21/9)
Age	24 (21.25-37)
BMI (kg/m ²)	29.3 (25.95-34.05)
Fat mass (kg)	20.3 (18.4-27.2)
Lean mass (kg)	59.2 (49.2-67.2)
Diabetes	24/30
HbA1c (mmol/mol;%)	52 (40-70); 6.9 (5.8-8.6)
Systolic BP (mmHg)	121 (111-127)
Diastolic BP (mmHg)	74 (67.5-80)
C-Peptide/Glucose (ng/ml)/(mg/dl)	0.047 (0.027-0.088)
Total cholesterol (mmo/l)	4.95 (4.2-6.3)
HDL (mmol/l)	0.89 (0.75-1.06)
Triglycerides (mmol/l)	3.25 (2.1-4.75)



Table 2. The hepatic phenotype of 30 patients with Alström Syndrome.


ID	Age	Sex	Ultrasound				AST <i>IU/L</i>	ALT <i>IU/L</i>	AST / ALT	Plts	Albu- -min <i>g/L</i>	Biliru- -bin $\mu\text{mol/L}$	ELF		Fibroscan	
			Texture	Contour Irregular	Spleen	Liver lesion							Value	Descriptor	LSE (IQR)	Descriptor
1	24	M	Normal	N	N	N	29	33	0.87	210	47	4	8.721	Mod		
2	27	M	Normal	N	N	N	32	37	0.86	180	45	3	8.750	Mod	7.8 (0.9)	NP
3	40	M	Normal	N	N	N	18	17	1.05	221	45	3				
4	23	F	Fatty	N	N	N	11	21	0.52	307	44	5	8.344	Mod	4.4 (1.0)	NP
5	30	F	Normal	N	N	Y	49	73	0.67	324	49	8	9.340	Mod	9.0 (1.7)	Predictive
6	44	M	Coarse	Y	N	N	25	53	0.47	151	40	5	9.903	Severe	4.8 (1.3)	NP
7	30	M	Fatty	N	N	N	29	83	0.34	244	55	5	7.732	Mod	5.1 (1.4)	NP
8	22	M	Fatty	N	N	N	29	109	0.26	244	47	6	9.294	Mod	12.6 (1.6)	Predictive
9	34	F	Fatty	N	N	N	16	25	0.64	308	44	4	9.740	Mod		
10*	19	M	Fatty	N	N	N	38	76	0.5	164	45	4	9.280	Mod		
11*	19	M	Fatty	Y	Y	N	32	48	0.66	236	54	5	7.590	None	13.9 (1.9)	Predictive
12*		M	Fatty	N	N	N	34	77	0.44	129	41	11	10.13	Severe	6.3 (0.7)	NP
13	22	M	Fatty	N	N	N	44	76	0.57	292	48	9	8.622	Mod	5.1 (1.6)	NP
14	20	M	Normal	N	N	N	32	43	0.74	247	47	4	10.28	Severe	6.0 (1.8)	NP
15*	19	M	Fatty	N	Y	N	35	76	0.46	183	44	7			11.1 (2)	Predictive
16	22	M	Fatty	N	Y	N	58	142	0.40	244	49	5	10.28	Severe	11.8 (0.2)	Predictive
17	21	M	Fatty	N	Y	N	126	209	0.60	300	47	4	9.489	Mod		
18		M	Coarse	Y	N	N	55	29	1.89	92	36	5	9.527	Mod	9.2 (1.8)	Predictive
19	20	M	Fatty	N	N	N	N/A			225	47	5			5.2 (0.9)	


20	20	F	Normal	N	N	N	18	19	0.94	144	45	6	9.643	Mod	4.2 (1)	NP
21	27	F	Normal	N	N	N	17	16	1.06	201	43	5	8.075	Mod	7.2 (1.9)	NP
22	22	F	Fatty	N	N	N	26	66	0.39	254	46	6	10.16	Severe	14.4 (0.4)	Predictive
23	51	M	Coarse	Y	N	N	28	37	0.75	240	49	4	10.31	Severe	9.6 (1.3)	Predictive
24	21	M	Fatty	N	N	N	34	67	0.50	280	46	9	8.673	Mod	4.9 (1.3)	NP
25	47	M	Fatty	N	N	N	17	21	0.81	203	48	10	7.922	Mod	12.9 (2.9)	Predictive
26	21	F	Cirrhotic	Y	Y	N	27	34	0.79	274	45	7	9.852	Severe	13 (2.9)	Predictive
27*	25	M	Fatty	Y	Y	Y	96	65	1.47	208	39	32				
28*	41	M					31	80	0.38	133	43	31	12.4	Severe		
29*	23	M					73	50	1.46	36	35	28				
30*	39	F					49	46	1.07	154	40	6	9.48	Mod		


Table 3. Histological analysis of livers of patients with Alström syndrome.


ID	Gender	Sample	ELF		Fibroscan		Liver biopsy interpretation					
			Value	Descriptor	Value (IQR)	Descriptor	Steatosis	Inflammation	Ballooning	Total NAS	Kleiner Fibrosis	Comment
10	M	Biopsy	9.280				3	1	2	6	1c	Steatohepatitis
11	F	Biopsy	7.590	None	13.9 (1.9)	Predictive	2	1	1	4	3	Steatohepatitis. Early bridging.
12	M	Post mortem	10.13	Severe	6.3 (0.7)	NP	1	0	0	1	1c	change, does not amount to SH, mild portal fibrosis only
15	M	Biopsy			11.1 (2)	Predictive	1	1	1	3	3	Steatohepatitis
27	M	Post mortem					1	1	2	4	4	In keeping with end stage Steatohepatitis.














Supplementary Table S1. The ALMS1 mutations of the patients with Alström syndrome.

ID	Mutation
1	c.2041C>T / c.2041C>T
2	c.6823C>T / c.9535C>T
3	c.2822T>A / c.10775delC
4	c6584delA / c.8832C>G
5	c.8002C>T / c.10879C>T
6	c.8995C>T / c.9001C>T
7	c.6895delG / c.6895delG
8	c.6526C>T / c.11101C>T
9	c.11101C>T
10	c.10769delC / c.5356A>G
11	c.6823C>T / c.9535C>T
12	c.1729delA / c.10477C>T
13	c6526C>T / c.11101C>T
14	c.8932C>T / c.5356A>G
15	c.4937C>A
16	c.7544-200_767+1110del / c.7544-200_767+1110del
17	c.4937C>A / c.4937C>A
18	c.10769delC / c.11410C>T
19	c.7544-200_767+1110del / c.7544-200_767+1110del
20	c.2041C>T / c.2041C>T
21	c.2218dupA / c.1069C > T
22	c.5075delC / c.5075delC
23	c.10483C>T / c.10775delC

24	c.6526C>T / c.11101C>T
25	c.1874A>G
26	c.7911dupC
27	c.10769delC/c.10986G>A
28	c.10769delC / c.10477C>T
29	Not available
30	c.10775delC /

Supplementary Table S2. Clinical characteristics of 6 patients with Alström syndrome and 9 controls who underwent abdominal subcutaneous adipose tissue biopsy.

(BMI=body mass index; HDL=high density lipoprotein cholesterol, ALT=Alanine aminotransferase, AST=Aspartate transaminase, ELF=Enhanced liver fibrosis panel)

(* $p<0.05$)

<i>Clinical characteristics</i>	<i>Alström syndrome</i> (n=6) ;(Cohort)	<i>Control (n=9)</i>
<i>Age (years)</i>	22 (20.5-23.5) ; 24 (21.3-37)	31 (25-35)
<i>Gender (male/female)</i>	4/2 ; 21/9	0/9
<i>BMI (kg/m²)</i>	29 (26-33.6); 29.3 (26-34)	26.6 (23.6-35.1)
<i>Diabetes (%)</i>	100% ; 80%	0%
<i>HbA1c (mmol/mol)/(%)</i>	47.5 (40.25-60)/6.5 (5.8-7.6)*; 52 (40-70)/ 6.9 (5.8-8.6)	35 (34-37)/5.4 (5.3-5.5)
<i>Total cholesterol (mmol/L)</i>	4.9 (4.35-5.075); 5 (4.2-6.3)	5.2 (4.5-5.6)
<i>HDL cholesterol (mmol/L)</i>	0.67 (0.66-0.74); 0.89 (0.75-1.06)	1.5 (1.1-1.9)
<i>Triglycerides (mmol/L)</i>	3.4 (2.7-4.3)*; 3.3 (2.1-4.75)	0.75 (0.7-1.4)

<i>ALT (IU/L)</i>	66 (48-76)*; 50 (33-76)	13.5 (10.75-18)
<i>AST (IU/L)</i>	29 (28-32) *; 32 (26-44)	15.5 (15-16.75)
<i>ELF (4/6)</i>		
<i>None to mild</i>	-	
<i>Moderate</i>	2	
<i>Severe</i>	2	
<i>FibroScan® (6/6)</i>		
< 8 kPa	1	
≥ 8 kPa	5	